A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study

Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction

(2021) R. Preston Mason et al.   AMERICAN JOURNAL OF MEDICINE

Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies

(2021) William S. Harris et al.   Nature Communications

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk

(2021) Steven E. Nissen et al.   JAMA Cardiology

Mechanisms of Atherosclerosis Induced by Postprandial Lipemia

(2021) Yixi Zhao et al.   Frontiers in Cardiovascular Medicine

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

(2020) R. Preston Mason et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Evolving Understanding and Approach to Residual Cardiovascular Risk Management

(2020) Devinder S. Dhindsa et al.   Frontiers in Cardiovascular Medicine

Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease

(2020) Meng Xia et al.   AMERICAN JOURNAL OF CARDIOLOGY

The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family

(2019) Gaetan Drouin et al.   BIOCHIMIE

Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial

(2019) Adam H Metherel et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association

(2019) Ann C. Skulas-Ray et al.   CIRCULATION

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

(2019) Jean-Claude Tardif et al.   NEW ENGLAND JOURNAL OF MEDICINE

Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study

(2019) Xiao-fei Guo et al.   PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers

(2017) Elliot Offman et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

(2017) Kevin C. Maki et al.   Journal of Clinical Lipidology

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile

(2013) Seth S. Martin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study

(2012) Michael H. Davidson et al.   Journal of Clinical Lipidology